Member Info for CuriousInvester6

I take a slightly different view, there were some major hurdles the company like may others encountered not least with Covid, supply issues, lock down, Ukraine etc which ultimately delayed this project with significant impacts on cash flow and a large burn rate. Further AIM listed stocks have suffered far more than anything else such as Nasdaq listed companies. It is very easy to look back and in hindsight the company could have taken a different financing course of action, for example when they announced achieving 230 Mev the stock in a risk on market would have soared. However I remain optimistic and have done so ever since share was suspended as ALL the executive and major shareholders have significant stakes in the business. The technology is proven and I just can not see all the major holders letting this go at the 11th hour before treating patients. The good news is no news....this is a complicated financial structure that requires many elements of regulatory procedures and process. The fact we have heard nothing means the deal is still being consumated with both sides incurring significant legal expense and the longer this goes on in my mind the better. As shareholders know the technology is going to be innovative and disruptive in a world desperate for LIGHT. I will be sorry if the company does not succeed not least because I have a very large holding but more loosing this tech and the many lives and especially children this could help. If the company goes bust the IP IMO opinion is almost worthless as the current executives and ADAM are integral to the success and all experts in this field and I doubt any would return if their equity and shareholdings are wiped out. I believe the company has until 30th December before de-listing but even then I understand they could apply for an extension...I am hopeful however that this month we will hear one way or the other. At present I am hoping no news is good news

On reviewing again the news, interesting this is announced in dollars with the investor providing up to $80 million. Any ideas who this could be?

At last some news, clearly the company must be at an advanced stage of negotiations. One can only assume that the Nerano article published earlier in October is one part of converting their substantial loan to equity.

These transactions are clearly complicated and have to be concluded in sequence.

I am more hopeful we should hear more progress and a General Meeting being called. Sufficient financing to get to first patient treatment in 2024 and completion of licensing will be a huge milestone and as such with substantially reduced debt the shares whilst diluted could do very well. GLA

Let’s hope it is a good partial sale / white knight investor, this technology is too valuable to fail at the 11th hour. The impact of this LINAC LIGHT technology will have immense benefits throughout the world and in the U.K. AVO have a robust plan to treat children who otherwise may not benefit. 🤞

This Recap plan is certainly taking its time, I am very hopeful however that no news really is good news as the company must be significantly advanced in negotiations otherwise the administrators would probably have been appointed.

Does anyone have any other views?

Hi Meldrew I do not believe any notification is required by an interested party. As announced on the 18th April 2023 please note the following:

The Takeover Panel has granted a dispensation from the requirements of Rules 2.4(b) and 2.6(a) of the Code such that any interested party participating in the formal sale process will not be required to be publicly identified (subject to note 3 to Rule 2.2 of the Code) and will not be subject to the 28-day deadline referred to in Rule 2.6(a), for so long as it is participating in the formal sale process.

I therefore believe all options are still on the table and hopefully the best one for all shareholders of which the directors are major holders will complete successfully

I really hoped we hear something soon, the question is - is no news good news? It must be a very time consuming and complicated set of events and I am getting a little concerned especially with the companies ability to retain staff.

Great to watch and just reinforces why AVO and LIGHT must succeed, the Christie Foundation Hospital highlighted while pioneering and successful required a significant larger footprint and much more shielding than AVO’s LIGHT. The Linac design of LIGHT generates lower levels of secondary radiation compared to cyclotron systems such as the Christie reducing the need for extensive shielding and therefore huge cost savings . As we know AVO’s LIGHT is designed therefore to be located in inner city areas occupying as planned within the basement area of 141-143 Harley Street which has just 15,000 sqft area in total.

AVO with CERN are clearly pioneers of the next generation of disruptive technology with LIGHT making proton beam therapy more accessible and cheaper for future generations and builds on their success with traditional cyclotron systems. Hospitals like the Christie will continue to play a major part and hopefully with AVO & CERN more proton beam therapy centres will be affordable and accessible to a wider population.

Https://citywire.com/new-model-adviser/news/wh-ireland-seeks-5m-to-avert-collapse-after-fca-talks/a2422668

Interesting development as they are handling any potential Nasdaq potential partners

I would hope we hear some developments next week regarding the consolidation, sub division and financing as everyday that passes is costing a great deal to those covering any bridging loan

IWTO that is a possibility however that would make the total number of shares even more totally “unwieldy” in the words of the directors. It is the only comment I find personally the most revealing, for that reason I expect as we move forward total shares issued will be less than today just depends how much.

With support from perhaps another major investor / current investors I believe all realise at this 11th hour and technically de risked position the shares are worth much more than the current market cap. Time will tell and I expect to hear a concrete plan by the end of July. GLA

I have been thinking about this Share consolidation and it is interesting with AVO's proposal that it will be followed by a subdivision/Share Split: being the opposite of a share consolidation, increasing the number of outstanding shares while proportionately decreasing the share price, usually done to make the shares more affordable and increase market liquidity. Which is clearly the only reason to move forward on this basis as no new issues will be issued at the prevailing nominal value of 25 pence.

As I understand the purpose of using both share consolidation and share split together would be to also sort out any convertible securities and adjust the nominal value of the shares simultaneously. Therefore by consolidating the shares first, the company can convert the convertibles on a consolidated basis, ensuring a more accurate conversion ratio. Then, through the subsequent share split, the nominal value of the shares can be reduced.

So hypothetically how could this work especially seeing the comment AVO make about the number of current shares?

“The Directors consider that the number of existing Ordinary Shares is not only unwieldly in volume for a company of Advanced Oncotherapy's market capitalisation, but when combined with the prevailing share price, is not conducive to an orderly market”.

So lets say they consolidate 10:1 and then assume a share split 1:2

If they are going to raise lets say the lower amount of £61.7 Million are they really going to be able to issue new shares lower than 20p??? they will still end up with 417 million shares versus now 542,573,869

Possible Equity Issue Price: 20 pence

Number of New Shares Required:

Total Equity Fundraising Amount / Issue Price for £61,700,000 @ 0.20 = 308,500,000 shares

Share Consolidation and Subdivisionn

Share Consolidation:

Assuming a consolidation ratio of 10:1, : (Even at 20:1 does not make a huge difference to overall sharevolume)

542,573,869 shares / 10 = 54,257,387 shares

Subdivision/Share Split:

Assuming a 1:2 share split, :

54,257,387 shares x 2 = 108,514,774 shares

To achieve the equity fundraising goal of £61.7 million, the company would have:

308,500,000 + 108,514,774 = 417,014.774 Issued shares

This is all hypothetical but I guess my point is focusing on the 'unwieldly' volume of shares and therefore perhaps unlikely to see an offer price any lower, which for all shareholders is very good news. If through this combined action they can also take out Odey the share price could do very well combining a capital raise which should be suffcient to totally complete all certfication and finally treating customers.

All thoughts welcomed, at the end of the day I just want the company to succeed, both as a shareholder and for the good of mankind.

Over £200 million as far as I am aware

Final results due this week, please BOD give some meaningful updates, shareholders should have an update on both Nasdaq discussions and an operational update especially certification and treating first patient definitive date. No regular updates at this time are destroying shareholder value. I hope we get some announcements and new additions to the board and investment announcements to turn this company around ASAP and enable the company to meet and complete their operational objectives.

Interesting indeed 1.8 million shares bought at 5p in a combination of large purchases in a little over half an hour. Hoping for positive funding news this week.

Interesting times, non dilutive options could of course involve a Nasdaq Listing company partnering with the company and injecting cash, I would be extremely surprised if serious discussions are not currently in play since the April announcement especially as the company has always been fully engaged in the USA and particularly with the Cleveland Clinic one of the companies highly respected world renowned research partners. I am also encouraged new participants are buying shares and joining the Loan note holders, as insiders they will have an uptodate perspective of how discussions are going.

The company continues to receive the support of some seriously wealthy LT shareholders and institutional investors who have not sold and who I guess if push came to shove at this 11th hour prior to treating first patients would also continue to support further, if I was them I would of course prefer all other options are first prioritised.

We must not forget also that this tech is proven, well protected by AVO patents and it will be disruptive in the market place. Competitors and major suppliers will be watching and perhaps even wishing to partner with the company.

Hoping for some positive indications of discussions this month.

I have been encouraged to see the major shareholders and a number of large new shareholders coming on board buying stock and supporting the convertible loan notes these past few weeks. The partcipation also by the board shows significant confidence. IMO positive progress will be forthcoming sooner probably than many expect and the shares should then re rate significantly to the upside, clearly AIM is just not the right market for this company which is still on track to treat new patients in H2 year having achieved all major hurdles not least achieving 230 MeV. The capital investment made by the company todate and progress in terms of expected delivery in H2 2023 defy any logic in my mind as to the current share price. While I am sad to see where the price is today after all the great work achieved by the BOD, I am also fortunate to have built a sizeable position. I am hoping to hear sooner rather than later progress on Nasqaq parties interested, a further Operations Update and progress with sales pipeline contractual negotiations. GLA, while these are challenging times I am excited by the oppotunities ahead for the company.

I do not believe they will be out of funds, reading between the lines it seems both directors and major shareholders will continue to support the company as they progress a number of avenues that will most benefit shareholders. Clearly DCNA seem to have thrown in the towel for one reason or other but unless we get another announcement no other major shareholder representing I guess around c 50% of the total shareholders has sold. The overhang alone on DCNA at some point will be cleared, IMO also the company will be of significant interest to some major players and as such this could prove to be a good entry point for them based on the £200 million so far invested in the technology which is on course to treat first patients H2 2023 and has achieved 230 MeV. There is always a risk but I have been buying. Good luck AVO and all shareholders.

It always surprises me the reacion of markets. The Annual Results were the best I have seen for some years with this company and the optimistc outlook augers well for the future. I liked this section:
"we are now more hopeful that the royalty income
will experience exponential growth from 2023 and beyond. Regarding SenstendTM in
China, we are working hard with our commercial partner Wanbang Biopharmaceutical
who are aiming to submit the NDA to NMPA in Q3 2023. And the same goes for the
US, where we continue to advance our NDA and more importantly have an agreed
roadmap with the FDA for its submission. Both these NDAs if approved will be game
changers for the Group.
We are excited about DLI with the launch of SenoClock@ in late 2022 as it has
managed to sign its first customers and will importantly expand its product offering in
2023, with introduction of MindAge@ to its SaaS@ platform."

Honestly I am not surpised by this collapse in the shareprice, investor confidence has gone, so many missed targets. I am pleased I sold out most of my holding at 36p and regret holding what I have left. The company should spend more time keeping investors up to date with progress following achieving 230 MEV, for example number of contractual discussions and more frequent news regarding progress with licensing. There have been to many generic news releases regarding the advantages of LIGHT which is simply not relevant until such time AVO has a fully licensed and operating system. I feel there are some industry insiders that probably know more of what is happening with the licensing schedule and maybe they are selling. Shares at an all time low for whatever the reason signifies to me that the BOD are simply not communicating as much as they should. Plus there are many investors that have been squeezed put by multiple fund raising at artificially high share prices backed by warrants. I like to think that this is still a £1 to £2 share but I fear a takeover or inability to raise sufficient capital going forward without real progress is going to limit any further progress. Ever hopefull

It will be interesting to read the Interim Results for further progress which are likely to be released tomorrow. Unfortunatley the share price responding very poorly following achieving 230 MeV is a symptom of the current market turbulence and also I suspect investors disapointment in past milestones just not being achieved, it takes a great deal of time to build investor confidence and it would appear that confidence over the past year has erroded. There just appears too many hurdles ahead before first patient treatment is achieved H2 2023, more progress on all the approvals and certfication I hope will be revealed soon and I contiune to wish the company and BOD well in bring this disruptive and amazing technology to fruition.